199 related articles for article (PubMed ID: 7900565)
1. [A study of effective administration of recombinant interferon-gamma in renal cell carcinoma regarding immunological influence on peripheral blood lymphocytes].
Kawata N; Ono M; Kodama M; Yamanaka Y; Hirakata H; Hirano D; Fuse T; Takimoto Y
Hinyokika Kiyo; 1995 Jan; 41(1):21-6. PubMed ID: 7900565
[TBL] [Abstract][Full Text] [Related]
2. [Immunological effect of recombinant interferon-gamma in renal cell carcinoma].
Kawata N; Ono M; Endo M; Ichinose T; Hamada T; Hirano D; Fuse T; Takimoto Y
Hinyokika Kiyo; 1993 Jun; 39(6):511-5. PubMed ID: 8337976
[TBL] [Abstract][Full Text] [Related]
3. [Immunological study of the postoperative adjuvant treatment with interferon gamma in patients with renal cell cancer--measurement of peripheral blood lymphocyte subsets with three color flow cytometry].
Yasunaga Y; Nishimura K; Miura H; Takatera H; Kuroda H; Kishimoto T; Fujioka H
Hinyokika Kiyo; 1995 Feb; 41(2):85-92. PubMed ID: 7702012
[TBL] [Abstract][Full Text] [Related]
4. [Long-term immunological study on postoperative adjuvant treatment with interferon-gamma in patients with renal cell carcinoma who underwent nephrectomy].
Miura H; Arai H; Matsuoka A; Yazawa K; Satoh E; Nishimura K; Honda M; Fujioka H
Hinyokika Kiyo; 1999 Feb; 45(2):79-83. PubMed ID: 10212778
[TBL] [Abstract][Full Text] [Related]
5. [Immunological assessment after radical nephrectomy for renal cell carcinomas pre-treated with interferon-gamma].
Onishi T; Machida T; Masuda F; Igarashi H
Hinyokika Kiyo; 1991 Jul; 37(7):671-8. PubMed ID: 1927765
[TBL] [Abstract][Full Text] [Related]
6. [Immunological study of interferon-gamma therapy for advanced renal cell carcinoma].
Aoyagi T; Murai M; Kimura F; Sawamura M; Asano T; Odajima K; Nagakura K; Nakamura H
Hinyokika Kiyo; 1992 Dec; 38(12):1357-60. PubMed ID: 1288223
[TBL] [Abstract][Full Text] [Related]
7. Inhibition of murine renal carcinoma pulmonary metastases by systemic administration of interferon gamma: mechanism of action and potential for combination with interleukin 4.
Hillman GG; Younes E; Visscher D; Hamzavi F; Kim S; Lam JS; Montecillo EJ; Ali E; Pontes JE; Puri RK; Haas GP
Clin Cancer Res; 1997 Oct; 3(10):1799-806. PubMed ID: 9815566
[TBL] [Abstract][Full Text] [Related]
8. [Effects of nephrectomy and interferon administration on immunological parameters in patients with renal cell carcinoma].
Arima K; Yanagawa M; Sugimura Y; Tochigi H; Kawamura J; Saitoh K; Yamazaki Y; Mori O; Oomoto Y; Nakagawa M
Hinyokika Kiyo; 1994 Jun; 40(6):469-74. PubMed ID: 8073952
[TBL] [Abstract][Full Text] [Related]
9. [Immunological effect of recombinant interferon-gamma on tumor infiltrating lymphocytes of renal cell carcinoma--relationship with clinical stage].
Kawata N; Takimoto Y; Hirano D; Yamamoto T; Hirakata H; Yamanaka Y; Okada Y; Chino K; Sugimoto S; Igarashi T
Hinyokika Kiyo; 1996 Jan; 42(1):1-4. PubMed ID: 8686575
[TBL] [Abstract][Full Text] [Related]
10. Correlation of clinical and immunological parameters of metastatic renal cell carcinoma patients undergoing therapy with interleukin 2, interferon-alpha and retinoic acid.
Elsässer-Beile U; Kölble N; Grussenmeyer T; Wetterauer U; Schultze-Seemann W
Anticancer Res; 1998; 18(3B):1883-90. PubMed ID: 9677439
[TBL] [Abstract][Full Text] [Related]
11. Immunological effects of treatment with sequential administration of recombinant interferon gamma and alpha in patients with metastatic renal cell carcinoma during a phase I trial.
Ernstoff MS; Gooding W; Nair S; Bahnson RR; Miketic LM; Banner B; Day R; Whiteside T; Titus-Ernstoff L; Kirkwood JM
Cancer Res; 1992 Feb; 52(4):851-6. PubMed ID: 1737346
[TBL] [Abstract][Full Text] [Related]
12. [Comparative study of the activating effects of recombinant human interleukin 2 and interferon-gamma on cell-mediated cytotoxicity against renal cell carcinoma in vitro].
Marumo K; Ueno M; Baba S; Muraki J; Deguchi N; Tazaki H
Gan To Kagaku Ryoho; 1987 Jun; 14(6 Pt 1):1825-9. PubMed ID: 3109327
[TBL] [Abstract][Full Text] [Related]
13. [Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases].
Wang H; Zhou FJ; Wang QJ; Qin ZK; Huang LX; Liu ZW; Han H; Li YQ; Chen SP; Xia JC
Ai Zheng; 2006 May; 25(5):625-30. PubMed ID: 16687087
[TBL] [Abstract][Full Text] [Related]
14. Immunological effects of recombinant interferon-alpha 2 in cancer patients.
Hengst JC; Kempf RA; Kan-Mitchell J; Pham AT; Grunberg SM; Kortes VL; Mitchell MS
J Biol Response Mod; 1983; 2(6):516-27. PubMed ID: 6663321
[TBL] [Abstract][Full Text] [Related]
15. Subcutaneous interleukin-2 in combination with vinblastine for metastatic renal cancer: cytolytic activity of peripheral blood lymphocytes.
Indrová M; Bubeník J; Jakoubková J; Símová J; Jandlová T; Helmichová E; Benesová K; Hesová M; Stáhalová V
Neoplasma; 1994; 41(4):197-200. PubMed ID: 7935991
[TBL] [Abstract][Full Text] [Related]
16. Clinical responses following nonmyeloablative allogeneic stem cell transplantation for renal cell carcinoma are associated with expansion of CD8+ IFN-gamma-producing T cells.
Harlin H; Artz AS; Mahowald M; Rini BI; Zimmerman T; Vogelzang NJ; Gajewski TF
Bone Marrow Transplant; 2004 Mar; 33(5):491-7. PubMed ID: 14716341
[TBL] [Abstract][Full Text] [Related]
17. Repeated administrations of interleukin (IL)-12 are associated with persistently elevated plasma levels of IL-10 and declining IFN-gamma, tumor necrosis factor-alpha, IL-6, and IL-8 responses.
Portielje JE; Lamers CH; Kruit WH; Sparreboom A; Bolhuis RL; Stoter G; Huber C; Gratama JW
Clin Cancer Res; 2003 Jan; 9(1):76-83. PubMed ID: 12538454
[TBL] [Abstract][Full Text] [Related]
18. [Results of low dosage cyclic interferon-gamma therapy of metastatic renal cell carcinoma].
Hofmockel G; Wirth MP; Heimbach D; Frohmüller HG
Urologe A; 1993 Jul; 32(4):290-4. PubMed ID: 8372410
[TBL] [Abstract][Full Text] [Related]
19. Results of two sequential phase II studies of interleukin-2 (IL2) in metastatic renal cell carcinoma and melanoma: high-dose continuous intravenous IL2 infusion and subcutaneous IL2 administration in combination with alpha interferon.
Hidalgo OF; Aramendía JM; Alonso G; Foncillas JG; Brugarolas A
Rev Med Univ Navarra; 1996; 40(3):6-12. PubMed ID: 9499820
[TBL] [Abstract][Full Text] [Related]
20. Antibody delivery and effector cell activation in a phase II trial of recombinant gamma-interferon and the murine monoclonal antibody CO17-1A in advanced colorectal carcinoma.
Weiner LM; Moldofsky PJ; Gatenby RA; O'Dwyer J; O'Brien J; Litwin S; Comis RL
Cancer Res; 1988 May; 48(9):2568-73. PubMed ID: 3128400
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
